SafeNest unveils ‘One Safe Place,' with plans to have it open by Oct. 30
LAS VEGAS (KLAS) — SafeNest unveiled a first-of-its-kind centralized hub for victims of domestic and sexual violence on Thursday, with plans to have it ready in about six months.
Clark County ranks No. 1 in the country for domestic violence homicides. Liz Ortenburger, CEO of SafeNest, said she's glad to be a part of this new initiative and bring awareness to the growing number of victims in the area.
'There had to be some change. I'm happy it's this and I'm glad the state chose to invest,' Ortenburger said.
Thursday's unveiling of 'One Safe Place' featured the ceremonial passing of the SafeNest purple key to symbolize the new campus.
The new space will provide over 500 individual survivor-focused services, including legal response, advocacy response, counseling, crisis response and housing services.
Victims can also get help with WIC, food stamps and social services. Lisa Lopez, a domestic violence survivor and now SafeNest board member, said having all of SafeNest's resources under one roof will help reach more victims.
'It's very hard when you have children, and you have jobs. It's long days of driving from place to place, waiting in long lines and waiting for appointments. So having all of this under one roof will significantly change a survivor's outcome to a positive one,' Lopez said.
The new hub is set to open Oct. 30. The new building must still be purchased and renovated with an estimated cost of $17 million. The state of Nevada is providing $9 million of the funding. SafeNest plans to launch a campaign to raise the rest.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and X. View source version on Contacts Investor Contact: Andrew McKibbenir@ Media Contact: Erin Murphymedia@
Yahoo
31 minutes ago
- Yahoo
42-year-old Wisconsin man arrested for 4th OWI after swerving in between multiple lanes
MIDDLETON, Wis. (WFRV) – A 42-year-old Wisconsin man was arrested for operating while intoxicated (OWI) on Tuesday morning after an officer saw him allegedly swerving between lanes. The Middleton Police Department reported that an officer was in the 6400 block of University Avenue around 2:50 a.m. on Tuesday, when the officer found a vehicle that was not staying in its lane. Multiple hurt in Sheboygan County crash involving dump truck, one severely injured During a traffic stop on the driver, identified as 42-year-old Darrell Ternes of Cross Plains, the officer noticed the scent of intoxicants from Ternes, who admitted to drinking before driving. A records check revealed that Ternes had three OWI convictions and that he had a revoked license. Ternes was subsequently issued traffic citations and arrested for a fourth OWI after field sobriety tests. No additional details are available. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
31 minutes ago
- Yahoo
Lansing inmate found guilty following 2024 escape
KANSAS CITY, Mo. — An inmate who escaped the Lansing Correctional Facility last year was found guilty this week. On Monday, a Leavenworth County jury found 55-year-old Bradley G. Verstraete guilty of aggravated escape from custody following a one-day trial. Motorcyclist killed after colliding with tractor-trailer in Kansas City He was serving an 8.5-year prison sentence for attempted murder and aggravated assault on a police officer in 2017 in Pratt County. He was . Surveillance footage showed Verstraete walking out without authorization. He was declared an escapee shortly thereafter. Verstraete was a minimum security inmate at the time of his escape. He was arrested the next day by Lansing police. Download the FOX4 News app on iPhone and Android He is scheduled to be sentenced on July 11. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
